	Xcelience, a contract drug manufacturer, announced that the company has received approval from the US Drug Enforcement Agency (DEA) to develop and manufacture Schedule I controlled substances.  he license extension completes company’s approval to handle both analytical and manufacturing of DEA Scheduled products, according to a company statement. 

	"Regulatory capability is a critical attribute for CDMOs," says Alex McClung, vice-president, quality at Xcelience. "This Schedule I-V license underscores our capability and extends our Suite of Services to a whole new class of therapeutic compounds."

	In addition, Xcelience announced that the company is expanding its pharmaceutical development services and manufacturing capacity by adding a new facility in the Tampa area to include more pharmaceutical development labs, manufacturing, quality assurance and packaging services.  

Manufacturing Services

Outsourcing

PharmTech News

Supplier News

PTSM: Pharmaceutical Technology Sourcing and Management-04-01-2015

Xcellience receives approval to handle both analytical and manufacturing of DEA Scheduled products.